Condition: Peripheral T-Cell Lymphoma Refractory · Sponsor: Second Affiliated Hospital of Soochow University
An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
This description comes directly from the study's public registry record.
Kang Lu, Master · 0086-15162517756 · 15162517756@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Soochow University Suzhou | Suzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07598578